Homeobox genes encode transcription factors known to be important morphogenic regulators during embryonic development. An increasing body of work implies a role for homeobox genes in both hematopoiesis and leukemogenesis. In the present study we have analyzed the role of the homeobox gene, HOXB6, in the program of differentiation of the myeloid cell lines, NB4 and HL60. HOXB6 expression is transiently induced during normal granulocytopoiesis and monocytopoiesis, with an initial induction during the early phases of differentiation, followed by a blockade of expression at early maturation. The enforced expression of HOXB6 in promyelocytic NB4 cells or in myeloblastic HL60 cells elicited inhibition of the granulocytic or monocytic maturation, respectively. Furthermore, HOXB6 was frequently expressed (18 out of 49 cases) in AMLs lacking major translocations while it was expressed at very low frequency (two out of 47 cases) in AMLs characterized by PML/RAR-␣, AML-1/ETO, CBF␤/MYH11 fusion and rearrangements of the MLL gene at 11q23. According to these observations, we suggest that a regulated pattern of HOXB6 expression is required for normal granulopoiesis and monocytopoiesis. Abnormalities of the HOXB6 expression may contribute to the development of the leukemic phenotype.
Introduction
Hematopoiesis depends on a complex series of cellular events which requires both the maintenance of a pool of hematopoietic stem cells in an undifferentiated state and their maturation first to multipotent hemopoietic progenitors and then to committed progenitors which first generate a progeny of differentiated cells (hemopoietic precursors) and then the mature cellular elements of blood (reviewed in Ref. 1) . The molecular mechanisms that lead to the generation of a progeny of progressively maturing cells starting from pluripotent hemopoietic stem cells are poorly understood and begin only in part to be elucidated. 2 The process of hemopoietic differentiation seems to be orchestrated at the molecular level by a series of transcription factors which act according to a hierarchic pattern and following differentiation-specific pathways. 2 Among these transcription factors a relevant role seems to be played by homeobox (HOX) genes.
Products of HOX genes are localized in the nucleus and represent a major class of transcription factors controlling cellular proliferation/differentiation during early embryonic development. 3 Homeogenes, originally described in Drosophila melanogaster, are organized in gene clusters evolutionarly conserved. 4, 5 In humans the homeobox genes are Many of the HOX genes have been implicated in the regulation of both normal and leukemic hematopoiesis (reviewed in Refs 7-10). It seems clear that HOX genes are expressed in CD34 + cells and modulated according to stage and lineagespecific patterns. Particularly, HOXB genes on the 3′ cluster side are highly expressed in primitive CD34 + populations 9, [11] [12] [13] [14] and are colinearly expressed during differentiation of myeloid, erythroid and lymphoid cells. 12, 13, 15, 16 HOX gene mutations associated with leukemias are not known, but some leukemias are associated with irregular expression of HOX genes due to translocation or abnormal gene regulation. The HOX 11 gene is deregulated in T-ALL with the t(10;14) translocation, 17 while the HOX A9 is involved in the t(7;11) translocation present in AML classified as M2-M4 by French-American-British (FAB), that juxtaposes the complete HOX A9 gene to a gene for nucleoporin NUP98. 18 Concerning HOXB6 expression, we have shown that this homeobox is expressed in human hematopoietic progenitor cells (HPCs) induced to differentiate into granulocytic lineage, and that a blockade of its expression in HPCs specifically inhibits granulomonocytic colony formation. 13 However, the HOXB6 gene could also be relevant for fetal erythropoiesis, as suggested by studies in murine embryos. 19 Finally, preliminary observations based on the analysis of a few acute leukemia patients showed the expression of HOXB6 in some acute myeloid leukemias. 20 In this study we have retrovirally transduced the HOXB6 gene in promyelocytic NB4 cells and in myeloblastic HL60 and investigated the effects of its enforced and deregulated expression, showing an inhibition of the granulocytic and monocytic maturation, respectively.
Since protein products resulting from chromosomal translocations occurring in the human acute leukemias can interfere with regulated expression of genes that control normal hematopoiesis, 21 including HOX genes, it seemed of interest to evaluate the expression pattern of HOXB6 in acute myeloid leukemias. HOXB6 mRNA was found to be expressed at variable levels in about 35% of acute myeloid leukemias classified as M1, M2, M4, M5 and M6 by FAB. By contrast, almost all AMLs (45 out of 47) characterized by fusion genes underlying most common translocations (PML/RAR-␣, AML-1/ETO, CBF␤/MYH11 and rearrangements of the MLL gene) showed HOXB6 expression to be absent.
According to these observations we suggest that a regulated pattern of HOXB6 expression is required for normal granulopoiesis and monocytopoiesis. Abnormalities of HOXB6 expression in acute leukemia may contribute to the development of the leukemic phenotype.
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Materials and methods
Cloning of HOXB6 gene
Total RNA was extracted from human embryonal carcinoma cell line NT2/D1 induced to differentiate by all-trans retinoic acid (ATRA)10 −5 m. The RNA extraction was performed by the standard guanidinium thiocianate-CsCl technique. Two micrograms of total RNA were reverse transcribed (RT) with oligo (dT) as the primer. An aliquot of RT-RNA was amplified using pfu DNA polymerase (Stratagene, La Jolla, CA, USA) and the following primers: forward-primer CCCAATCTCGGAT ATACTAC, reverse-primer CTCGGGTGGGGGAGCCAGGA. 22 The PCR reaction mix was then directly ligated into the pCRScript Amp SK(+) (Stratagene) and used for bacterial transformation. A vector possessing the correct insert (674 bp) was identified and sequenced to confirm identity with published sequence of HOXB6. 22 
Retroviral generation and infection of NB4 and HL60 cell lines
Briefly, the HOXB6 cDNA region encompassing the complete coding sequence was subcloned at the BAMHI site of the PINCO retrovirus. 23 Viral supernatant was produced by transient transfection of Phoenix packaging cells with retroviral construct as described in Ref. 23 . NB4 and HL60 cell line infection was obtained by three cycles of centrifugation of the cells in viral supernatant at 1800 r.p.m. for 40 min in the presence of 4 g/ml of polybrene.
Hematopoietic growth factors and cell culture
Recombinant human growth factors were obtained from standard commercial sources. 24, 25 Iscove's medium was freshly prepared weekly.
Cell lines HL60 and NB4 were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS).
Adult peripheral blood (PB) HPC purification and clonogenic assay
HPCs were purified from PB buffy coat according to the method previously reported 24 and subsequently modified as described. 26 
HPC granulopoietic (G) and monocytopoietic (M) liquid suspension culture
Step IIIP HPCs were seeded (5 × 10 4 cells per ml) and grown in liquid FCS − medium supplemented in G cultures with low amounts of IL-3 (1 U/ml) and GM-CSF (0.1 ng/ml) and a saturating amount of G-CSF (10 ng/ml) as described; 26 in M cultures with Flt3 ligand (100 ng/ml), IL-6 (10 ng/ml) and M-CSF (10 ng/ml) as described. 27 Cells were incubated in a fully humidified atmosphere of 5% CO 2 /5% O 2 /90% N 2 and were periodically counted and analyzed for cell morphology, membrane phenotype and HOXB6 gene expression.
Reverse-transcription polymerase chain reaction (RT-PCR) analysis
Total RNA was extracted by the standard guanidium thiocyanate-CsCl in the presence of 12 g of Escherichia coli rRNA or by the guanidium thyocyanate/acid phenol method 28 technique.
RNA was reverse-transcribed (Moloney murine leukemia virus; BRL, Gaithersburg, MD, USA) with oligo (dT) (BRL) as a primer. The products were equalized by amplification of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or human ribosomal protein S26 genes. cDNA from NT2/D1 teratocarcinoma cells induced to differentiate for 14 days with ATRA 10 −5 m 29 was normalized together with normal and leukemic cell cDNAs: teratocarcinoma RT-RNA was used as positive control in each PCR.
To evaluate HOXB6 expression, an aliquot of cDNA (ෂ30 ng) was amplified within the linear range by 35 PCR cycles (the cycle number was chosen on the basis of doseresponse curve for the NT2/D1 templates and analysis of aliquots of PCR reactions removed at different PCR cycles) using the following primers: forward-primer CTTTGCCACTTC CTCCTATTAC, reverse-primer CCAGACATACACACGTTAC CAG. This amplification generated a 318 bp fragment of human HOXB6 gene. 22 PCR products were verified by Southern blotting utilizing an internal oligomer as a probe.
Evaluation of mRNA levels was performed by densitometric analysis (Instant Imager, Packard, Canberra, Australia).
Cell surface marker and morphology analysis of HPC cultures
To evaluate the differentiation of HPCs along the E and M lineages the cells were stained with the following monoclonal antibodies labeled either with FITC or PE: anti-CD34, anti-CD15, anti-CD14 (Pharmingen, San Diego, CA, USA). Fluorescent cells were analyzed with a flow cytometer (FACS Scan, Becton Dickinson, San Diego, CA, USA).
For cell morphology analysis cytospin preparations of cells were performed at different days of culture and stained with May-Grü nwald-Giemsa. At least 200 cells were counted and classified according to their differentiation/maturation stage.
Cell surface and morphology analysis of NB4 and HL60 cells
To evaluate the granulocytic differentiation capacities of both NB4 cells transduced with the empty vector containing only the reporter gene GFP (GFP NB4) or transduced with the HOXB6 (HOXB6 NB4), these cells were grown in vitro for 5-7 days in the presence of different doses of ATRA (from 10 −9 to 5 × 10 −7 m) and then analyzed for both cell surface markers and cell morphology. For analysis of cell surface membrane antigens the cells were labeled with the following PE-labeled monoclonal antibodies: anti-CD11a, anti-CD11b, antiCD11c, anti-CD15, anti-CD18 and anti-CD54 (all from Pharmingen). Fluorescent cells were analyzed as above and the results are expressed in terms of both the percentage of positive cells and mean fluorescent intensity, expressed in arbitrary units.
To evaluate the monocytic differentiation capacities of HL60 cells transduced either with the empty vector (GFP HL60) or with the HOXB6 gene (HOXB6 HL60), these cells were grown for 4 days in the presence of 1␣-25OH-VitD3 (250 g/ml) and then analyzed for cell surface markers and cell morphology. For analysis of cell surface membrane antigens the cells were labeled with the following PE-labeled monoclonal antibodies: anti-CD11a, anti-CD11b, antiCD11c, anti-CD18, anti-CD14 and anti-CD54 (all from Pharmingen). Fluorescent cells were analyzed as above.
Leukemic patient samples
Cryopreserved cell samples from 96 patients with acute myeloid leukemia, gathered from a single institution, were studied and subclassified according to FAB nomenclature. The original samples contained a range of 20 to 500 × 10 6 cells each and Ͼ80% blastic infiltration. Leukocytes were isolated by Ficoll-Hypaque density centrifugation, lysed in guanidine and freezed in liquid nitrogen. RNA was isolated by the guanidium thyocyanate/acid phenol method. 28 All the samples were analyzed for the presence of PML/RAR-␣, AML-1/ETO and CBF-␤/MYH11 fusion transcripts according to the primers, protocols and criteria of the European BIOMED1 Concerted Action for standardization of minimal residual disease (MRD) studies in acute leukemia. 30 All assays were carried out using appropriate positive (cDNAs from the NB4, KASUMI 1 and ME-1 cell lines) and negative controls (all reagents + H 2 O). Controls as well as samples were amplified in parallel with GAPDH primers, as internal control. MLL rearrangements were evaluated by Southern blot analysis using 10 g of high molecular weight DNA electrophoresed, blotted and hybridized with the appropriate 32 P-labeled probe. 31 
Statistical analysis
Patient characteristics and complete remission rates were compared using the chi-square test. Overall survival time was calculated from the rate of diagnosis until death or at last follow-up examinations. Survival curves were estimated using the product-limit method of Kaplan-Meier and were compared using the log-rank square.
Results
HOXB6 expression during normal granulocytic and monocytic differentiation
Using specific unilineage cell culture systems, allowing the selective differentiation/maturation of purified HPCs along either the granulocytic or monocytic lineages, [25] [26] [27] we have evaluated HOXB6 mRNA expression by RT-PCR during the different stages of granulocytopoiesis and monocytopoiesis. HOXB6 mRNA was only scarcely expressed in quiescent HPCs and its expression markedly increased during the initial stages of both granulocytic and monocytic differentiation, with a peak of expression around day 5 of culture ( Figure 1) . At later stages of differentiation/maturation, HOXB6 mRNA progressively declined, being undetectable or detectable only at very low levels in mature neutrophils and monocytes, respectively.
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Figure 1
RT-PCR analysis of HOXB6 mRNA in purified HPCs differentiating along the granulocytic (a) or monocytic (b) lineages. HOXB6 mRNA levels were investigated also in circulating neutrophils (G) and monocytes (Mo), as well as in the positive control, ie ATRAinduced teratocarcinoma cells (C + ).
Enforced expression of HOXB6 in NB4 promyelocytic cells impaired granulocytic maturation
Given this pattern of HOXB6 expression during the normal granulocytic and monocytic differentiation it seemed of inter- est to evaluate a possible role of this gene in the control of granulo-monocytic differentiation.
To evaluate this possible role we transduced with a retroviral vector expressing the HOXB6 gene (Figure 2 ) a leukemic cell line capable of differentiating to granulocytes, such as NB4 cells. The analogous vector containing GFP alone was used as a control (GFP).
NB4 cell line did not display HOXB6 mRNA expression detectable at the level of sensitivity of RT-PCR and RNAse protection techniques (data not shown). In contrast, NB4 cells transduced with HOXB6 gene under the control of a retroviral promoter constitutively expressed HOXB6 mRNA, at a level which remained constant during the differentiation ATRA induced (Figure 3a) . We evaluated the capacity of GFP-NB4 as well as HOXB6-NB4 cells to undergo granulocytic differentiation using ATRA as a chemical inducer of neutrophilic maturation. GFP-NB4 cells exhibited morphological and phenotypical changes (a marked enhancement of CD54, CD11b and CD18 expression) typically associated with induction of granulocytic maturation, while these changes were only scarcely observed in HOXB6 expressing NB4 cells (Figure 3b) .
ATRA dose-response studies showed that at all doses of the chemical inducer HOXB6-NB4 cells displayed a reduced granulocytic maturation as compared to those observed in GFP-NB4 cells, as evidenced by analysis of the levels of CD54 and CD18 achieved after treatment with different doses of ATRA (Figure 4 ).
Figure 4
Dose-response analysis of the effects of increasing concentrations of ATRA on CD54 and CD18 expression in GFP and HOXB6-NB4 cells, analyzed at day 7. A representative experiment is shown.
Constitutive HOXB6 expression in HL-60 cells inhibited monocytic maturation
Since the pattern of HOXB6 expression during normal monocytopoiesis strictly resembles that observed during granulopoiesis, it seemed of interest to evaluate whether a constitutive HOXB6 expression in HL-60 could impair the capacity of these cells to undergo monocytic maturation in response to treatment with 1␣25OH-VitD3. Wild-type HL-60 cells did not express HOXB6 mRNA at detectable levels by RT-PCR and RNAse protection (data not shown), while a high and constitutive HOXB6 expression was observed in HL-60 cells transduced with HOXB6 gene and such expression remained unmodified after incubation of the cells with 1␣25OH-VitD3, a chemical inducer of monocytic maturation (Figure 5a ). After 4 days of treatment with this inducer wild type (wt) as well as HL-60 cells transduced with the empty vector (GFP) underwent monocytic maturation according to morphological and phenotypical criteria. However, these changes were greatly inhibited in HL60 cells expressing the HOXB6 gene (Figure 5b ). The analysis of the kinetics of induction of CD14, a membrane antigen specifically expressed in monocytes, showed that this antigen was induced by 1␣25OH-VitD3 on Leukemia the large majority of HL60 cells (wt or transduced with the empty vector) at consistently high levels; however, the CD14 antigen was induced only on about 50% of HOXB6 cells and only at low levels ( Figure 5c ).
HOXB6 expression in AML
Given these effects of HOXB6 on granulocytic and monocytic maturation it seemed of interest to evaluate HOXB6 expression on leukemic blasts derived from AML patients. Ninety-six cases of AML, subdivided according to the FAB classification, were screened for HOXB6 expression.
Interestingly, a consistent proportion (18/49) of AMLs lacking major translocations were found to be HOX B6 + (ranging from 22 to 60% of AMLs classified as M1, M2, M4 M5 and M6 by FAB) (Table 1) ; the cases expressing the highest levels of HOXB6 mRNA were found among M2 and M4 leukemias ( Figure 6 ).
By contrast, almost all AMLs (45/47) characterized by fusion genes underlying most commons translocation showed HOX B6 expression to be absent (Table 2 ). In particular, leukemic blasts from 15 cases of M3 PML/RAR-␣ + were constantly HOXB6 negative (Table 2) M3 leukemic blasts tested negative for HOXB6 expression even after in vitro treatment with ATRA, which downregulates PML/RAR-␣ expression and induces granulocytic maturation of these cells (data not shown).
Clinical outcome according to HOXB6 expression was investigated in the group of 49 patients with normal karyotype.
Patients with positive HOXB6 expression and patients with negative HOXB6 expression had essentially identical complete remission rates of 66.6% and 62.7% (P = 0.43). There was a trend towards longer median survival in patients lacking HOXB6 expression: median survival 26 months (range 1-86) vs median survival of 15 months (range 1-84); however, this difference did not achieve statistical significance (P = 0.24).
Discussion
In recent years, several members of the homeobox gene family have been identified as important regulators of hemopoietic cell differentiation. The expression patterns of these genes have been extensively studied in cell lines and, to a less extent, in normal hemopoietic cells (reviewed in Refs 9 and 10). Several of the HOX genes exhibited a temporal pattern of expression, with a peak associated with the early stages of HPC differentiation and downregulation of several HOX genes being associated with later differentiation. 12, 13 HOXB6 is a prototype of these HOX genes, its expression being restricted to the early phases of HPC differentiation (Ref 13 and the present paper), with downmodulation at intermediate/late stages of maturation.
Given this peculiar pattern of expression it seemed of interest to evaluate the role of this HOX gene in granulocytopoiesis and in monocytopoiesis. Enforced expression of HOXB6 in NB4 and HL60 cell lines, which do not express HOXB6, elic- Expression was detected by RT-PCR analysis as shown in Figure 6 . Bands were quantitated by densitometric scanning of autoradiographs, using the value (+) when the band was similar to the positive control (ATRA-induced NT2/D1 teratocarcinoma cells). See also Figure 6 and Materials and methods section.
ited a marked inhibition of granulocytic and monocytic maturation, respectively. The inhibition of ATRA-induced granulocytic maturation of NB4 cells is particularly interesting, as retinoic acid is known to regulate homeobox gene expression, including HOXB6, in other cell types. 29 This inhibitory effect of HOXB6 on granulocytic and monocytic maturation suggests that a silencing of this HOX gene is required for the normal development of granulopoiesis and monocytopoiesis. It is of interest that the effects of HOXB6 are different from those previously reported for HOXB7 in the HL60 cellular system. In fact, overexpression of HOXB7 in these cells elicited an inhibition of ATRA-induced granulocytic maturation, but did not affect the monocytic maturation induced by 1␣25OH-VitD3. 32 However, at variance with HOXB6, HOXB7 expression was induced during VitD3-driven maturation of HL60 cells.
Previous studies on HOXB6 have suggested a possible role of this gene in the control of erythropoiesis. Thus, transfection of the K562 erythroid cell line with a HOXB6 antisense construct induced an increase of erythroid features, while an opposite phenomenon was observed when the cells were transfected with a HOXB6 sense. 11 Furthermore, it was shown that during embryonic/fetal murine development HOXB6 expression is closely associated with the regulation of the erythropoietic system. 19 In the present study, we show that a regulated pattern of HOXB6 expression is also required for normal granulocytic and monocytic differentiation.
There is growing evidence indicating that HOX proteins play a role in leukemic transformation (reviewed in Ref. 33 ):
(1) in AMLs, several HOXA, HOXB and HOXC genes are RT-PCR analysis of HOXB6 mRNA in leukemic blasts derived from AMLs lacking major translocations. Only positive cases are shown, see also expressed, while in lymphoid malignancies, HOXC genes are preferentially expressed; (2) in rare cases of leukemia HOX genes are mutated, such as the HOXA9 gene fused together with the nucleoporin gene as the consequence of the t(7;11) translocation. 18 This is the first study which reports the pattern of HOXB6 expression in a large number of AMLs. We observed HOXB6 expression in about 35% of AMLs lacking major translocations, with some cases of M2 and M4 leukemia expressing particularly high levels of HOXB6 mRNA (see Table 1 and Figure 6 ). The expression pattern of HOXB6 in AMLs does not seem to be related to the differentiation potential of the leuLeukemia kemic blasts in that it was similarly expressed in different subtypes of AML, including M1, M2, M4, M5 and M6.
Furthermore, with the exception of only two cases, HOXB6 expression was found to be absent in AMLs positive for the expression of leukemogenetic fusion proteins (such as PML/RAR-␣, MLI-1/ETO, CBF␤/MYH11 and MLL gene rearrangements). These AMLs account for about 40% of total AMLs and for the large majority (Ͼ90%) of AMLs with known oncogenetic molecular defects. 21 Since it was previously reported that HOXC6, paralogue to HOXB6, was expressed in AML-M3, 34 we analyzed the expression of this gene in all M3 blasts. We detected HOXC6 expression in three out 15 cases (data not shown).
In particular, M3 leukemias were constantly found to be negative for HOXB6 expression, which remained absent following ATRA treatment. Reasons underlying this finding are at present unclear to us. Nevertheless, it is of interest that also in two previous studies HOXA9 35 and HOXA10 36 were found to be expressed in all types of AMLs, with the constant exception of M3 leukemias. Based on those observations and on the results of the present study, it is tempting to suggest that HOX gene expression is suppressed in M3 leukemias probably through an aberrant signaling mediated by the PML/RAR-␣. 37 HOX gene expression in several cell types is stimulated following activation of retinoic acid receptors; 29 thus, it may be hypothesized that an aberrant signaling through the RAR-␣ fused with PML suppresses the stimulatory effect of normal RARs on HOX gene expression.
Whatever mechanism is involved in HOXB6 expression in AMLs, this phenomenon does not seem to be related to clinical outcome. This striking difference among different types of AMLs suggests that HOXB6 expression in AMLs could be specifically associated with leukemias whose molecular defects remain to be determined.
